Tag Archives: Malte Peters

Sandoz’s EGALITY trial results: equivalence in Psoriasis Area and Severity Index (PASI) 75 response rates at week 12 met

The EGALITY study met its primary endpoint demonstrating equivalent efficacy of Sandoz biosimilar etanercept candidate to the originator product at week 12 As a first-of-its kind, the confirmatory clinical safety and efficacy study compares originator etanercept to a biosimilar candidate … Read the full press release